Contribution of innate immune responses towards resistance to african trypanosome infections

Scandinavian Journal of Immunology

Volumn 75, Issue 1, 2012, Pages 5-15

  Namangala, B ^a  

^a UNIVERSITY OF ZAMBIA   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; AFRICAN TRYPANOSOMIASIS; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; COMPLEMENT SYSTEM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION CONTROL; INFECTION RESISTANCE; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE RESISTANCE; HUMANS; TRYPANOSOMA; TRYPANOSOMIASIS;

EID: 83455235522     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02619.x     Document Type: Review

References (99)

1. Barret MP. The trypanosomoses. Lancet 2003;362:1469-80.
2. Cross GAM. Cellular and genetic aspects of antigenic variation in trypanosomes. Annu Rev Immunol 1990;8:83-110.
3. Borst P, Rudenko G. Antigenic variation in African trypanosomes. Science 1994;264:1872-3.
4. Taylor KA. Immune responses of cattle to African trypanosomes: protective or pathogenic? Int J Parasitol 1998;28:219-40.
5. Stijlemans B, Guilliams M, Raes G, Beschin A, Magez S, De Baetselier P. African trypanosomosis: from immune escape and immunopathology to immune intervention. Vet Parasitol 2007;148:3-13.
6. Antoine-Moussiaux N, Magez S, Desmecht D. Contributions of experimental mouse models to the understanding of African trypanosomiasis. Trends Parasitol 2008;24:411-8.
7. Baral TN. Immunobiology of African trypanosomes: need of alternative interventions. J Biomed Biotechnol 2010;389153.
8. Kaushik RS, Uzonna JE, Gordon JR, Tabel H. Innate resistance to Trypanosoma congolense infection: differential production of nitric oxide by macrophages from susceptible Balb/c and resistant C57Bl/6 mice. Exp Parasitol 1999;92:131-43.
9. Namangala B, De Baetselier P, Noël W, Brys L, Beschin A. Alternative versus classical macrophage activation during experimental African trypanosomosis. J Leukoc Biol 2001;69:387-96.
10. Duleu S, Vincendendeau P, Courtois P et al. Mouse strain susceptibility to trypanosome infection: an arginase-dependent effect. J Immunol 2004;172:6298-303.
11. Drennan MB, Stijlemans B, Van Den Abbeele J et al. The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88-dependent. J Immunol 2005;175:2501-9.
12. Harris TH, Mansfield JM, Paulnock DM. CpG Oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes. Infect Immun 2007;75:2366-73.
13. Leppert BJ, Mansfield JM, Paulnock DM. The soluble variant surface glycoprotein of African trypanosomes is recognized by a macrophage scavenger receptor and induces I kappa B alpha degradation independently of TRAF6-mediated TLR signaling. J Immunol 2007;179:548-56.
14. Lopez R, Demick KP, Mansfield JM, Paulnock M. Type I IFNs play a role in early resistance, but subsequent susceptibility, to the African trypanosomes. J Immunol 2008;181:4908-17.
15. Stijlemans B, Vankrunkelsven A, Brys L, Raes G, Magez S, De Baetselier P. Scrutinizing the mechanisms underlying the induction of anemia of inflammation through GPI-mediated modulation of macrophage activation in a model of African trypanosomiasis. Microbes Infect 2010;12:389-99.
16. De Baetselier P, Namangala B, Noël W et al. Alternative versus classical macrophage activation during experimental African trypanosomosis: a review. Int J Parasitol 2001;31:574-86.
17. Okomo-Assoumou MC, Daulouede S, Lemesre JP, N'zila-mouanda A, Vincendeau P. Correlation of high serum tumor necrosis factor-alpha with disease severity in human African trypanosomiasis. Am J Trop Med Hyg 1995;53:539-43.
18. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006;97:55-64.
19. MacLean L, Odiit M, Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol 2007;211:16-22.
20. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 2010;375:148-59.
21. Joshi PP, Shegokar VR, Powar RM et al. Human trypanosomiasis caused by Trypanosoma evansi in India: the first case report. Am J Trop Med Hyg 2005;73:491-5.
22. Moloo SK, Zweygarth E, Sabwa CL. A comparison of susceptibility to stocks of Trypanosoma simiae of Glossina pallidipes originating from allopathic populations in Kenya. Med Vet Entomol 2008;9:224-8.
23. Desquesnes M, Davila AMR. Applications of PCR-based tools for detection and identification of animal trypanosomes: a review and perspectives. Vet Parasitol 2002;109:213-31.
24. Brun R, Hecker H, Lun ZR. Trypanosoma evansi and Trypanosoma equiperdum: distribution, biology, treatment and phylogenetic relationship: a review. Vet Parasitol 1998;79:95-107.
25. Naessens J. Bovine trypanotolerance: a natural ability to prevent severe anaemia and haemophagocytic syndrome. Int J Parasitol 2006;36:521-8.
26. O'Gorman GM, Park SD, Hill EW et al. Transcriptional profiling of cattle infected with Trypanosoma congolense highlights gene expression signatures underlying trypanotolerance and trypanosusceptibility. BMC Genomics 2009;10:207.
27. Mulla AF, Rickman LR. How do African game animals control trypanosome infection? Parasitol Today 1988;4:352-4.
28. De Gee ALW, Levine RR, Mansfield JM. Genetics of resistance to the African trypanosomes VI. Heredity of resistance and variable surface glycoprotein-specific immune responses. J Immunol 1988;140:283-8.
29. Mitchell LA, Pearson TW. Antibody responses in resistant and susceptible mice infected with Trypanosoma congolense. Immunology 1986;57:297-303.
30. Molina-Portela Mdel P, Samanovic M, Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med 2008;205:1721-8.
31. Vanhollebeke B, Truc P, Poelvoorde P et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-1. N Engl J Med 2006;355:2752-6.
32. Lugli EB, Pouliot M, Molina-Portela Mdel P et al. Characterization of primate trypanosome trypanolytic factors. Mol Biochem Parasitol 2004;138:9-20.
33. Hajduk SK, Moore DR, Vasudevacharya J et al. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J Biol Chem 1989;264:5210-7.
34. Pays E, Vanhollebveke B, Vanhamme L et al. The trypanolytic factor of human serum. Nat Rev Microbiol 2006;4:477-86.
35. Vanhollebeke B, Nielsen MJ, Watanabe Y et al. Distinct roles of haptoglobin-related protein and apolipoprotein L-1 in trypanolysis by human serum. Proc Natl Acad Sci U S A 2007;104:4118-23.
36. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P et al. Apolipoprotein L-1 is the trypanosome lytic factor of human serum. Nature 2003;422:83-7.
37. Wheeler RJ. The trypanolytic factor-mechanism, impacts and applications. Trends Parasitol 2010;26:457-64.
38. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005;309:469-72.
39. Poelvoorde P, Vanhamme L, Van Den Abbeele J et al. Distribution of apolipoprotein L-1 and trypanosome lytic activity among primate sera. Mol Biochem Parasitol 2004;134:155-7.
40. Vanhollebeke B, Pays E. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol Microbiol 2010;76:806-14.
41. Vanhollebeke B, De Muylder G, Nielsen MJ et al. A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. Science 2008;320:677-81.
42. Vanhollebeke B, Uzureau P, Monteyne D, Pérez-Morga D, Pays E. Cellular and molecular remodelling of the endocytic pathway during differentiation of Trypanosoma brucei bloodstream forms. Eukaryot Cell 2010;9:1272-82.
43. Xong HV, Vanhamme L, Chamekh M et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998;95:839-46.
44. Lecordier L, Vanhollebeke B, Poelvoorde P et al. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog 2009;5:e1000685.
45. Thomson R, Molina-Portela P, Mott H et al. Hydrodynamic gene delivery of baboon trypanosome lytic factor eliminates both animal- and human-infective African trypanosomes. Proc Natl Acad Sci U S A 2009;106:19509-14.
46. Reduth D, Grootenhuis JG, Olubayo RO et al. African buffalo serum contains novel trypanocidal protein. J Eukaryot Microbiol 1994;41:95-103.
47. Muranjan M, Wang Q, Li Y et al. The trypanocidal Cape buffalo serum protein is xanthine oxidase. Infect Immun 1997;65:3806-14.
48. Wang J, Van Praagh A, Hamilton E et al. Serum xanthine oxidase: origin, regulation and contribution to control of trypanosome parasitemia. Antioxid Redox Signal 2002;4:161-78.
49. Pan W, Ogunremi O, Wei G, Shi M, Tabel H. CR3 (CD11b/CD18) is the major macrophage receptor for IgM antibody-mediated phagocytosis of African trypanosomes: diverse effect on subsequent synthesis of tumor necrosis factor and nitric oxide. Microbes Infect 2006;8:1209-18.
50. Devine DV, Falk RL, Balber AE. Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense. Infect Immun 1986;52:223-9.
51. Ferrante A, Allison AC. Alternative pathway activation of complement by African trypanosomes lacking a glycoprotein coat. Parasite Immunol 1983;5:491-8.
52. Otesile EB, Lee M, Tabel H. Plasma levels of proteins of the alternative complement pathway in inbred mice that differ in resistance to Trypanosoma congolense infections. J Parasitol 1991;77:958-64.
53. Albright JW, Albright JF. Murine natural resistance to Trypanosoma lewisi involves complement component C3 and radiation-resistant, silica dust sensitive effector cells. Infect Immun 1985;47:176-82.
54. Russo DC, Williams DJ, Grab DJ. Mechanisms for the elimination of potentially lytic complement-fixing variable surface glycoprotein antibody-complexes in Trypanosoma brucei. Parasitol Res 1994;80:487-92.
55. Van Velthuysen ML, Mayen AE, Prins FA, De Heer E, Bruijn JA, Fleuren GJ. Phagocytosis by glomerular endothelial cells in infection-related glomerulopathy. Nephrol Dial Transplant 1994;9:1077-83.
56. Hertz CJ, Filutowicz H, Mansfield JM. Resistance to the African trypanosomes is IFN-γ dependent. J Immunol 1998;161:6775-83.
57. Tabel H, Kaushik RS, Uzonna J. Experimental African trypanosomiasis: differences in cytokine and nitric oxide production by macrophages from resistant and susceptible mice. Pathobiology 2000;67:273-6.
58. Gomez-Rodriquez J, Stijlemans B, De Muylder G et al. Identification of a parasitic immunomodulatory protein triggering the development of suppressive M1 macrophages during African trypanosomiasis. J Infect Dis 2009;200:1849-60.
59. Mansfield JM, Paulnock DM. Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol 2005;27:361-71.
60. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004;4:499-511.
61. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76.
62. Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MAJ, De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moities of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol 1998;160:1949-56.
63. Stijlemans B, Baral TN, Guilliams M et al. A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology. J Immunol 2007;179:4003-14.
64. Mensa-Wilmot K, Garg N, McGwire BS et al. Roles of free GPIs in amastigotes of Leishmania. Mol Biochem Parasitol 1999;99:103-16.
65. Gobert AP, Daulouede S, Lepoivre M et al. l-Arginine availability modulates local nitric oxide production and parasite killing in experimental trypanosomiasis. Infect Immun 2000;68:4653-7.
66. Noel W, Hassanzadeh G, Raes G et al. Infection stage-dependent modulation of macrophage activation in Trypanosoma congolense-resistant and -susceptible mice. Infect Immun 2002;70:6180-7.
67. Namangala B, De Baetselier P, Noël W, Brys L, Magez S, Beschin A. Relative contribution of IL-10 and IFN-γ towards resistance to African trypanosomosis. J Infect Dis 2001;183:1794-800.
68. Guilliams M, Oldenhove G, Noel W et al. African trypanosomiasis: naturally occurring regulatory T cells favour trypanotolerance by limiting pathology associated with sustained type-I inflammation. J Immunol 2007;179:2748-57.
69. Guilliams M, Bosschaerts T, Herin M et al. Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis 2008;198:781-91.
70. Bosschaerts T, Guilliams M, Stijlemans B et al. Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-γ and MyD88 signaling. PLoS Pathog 2010;6:e1001045.
71. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82.
72. Guilliams M, Movahedi K, Bosschaerts T et al. IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathology during parasitic infection. J Immunol 2009;182:1107-18.
73. Dagenais TR, Freeman BE, Demick KP, Paulnock DM, Mansfield JM. Processing and presentation of variant surface glycoprotein molecules to T cells in African trypanosomiasis. J Immunol 2009;183:3344-55.
74. Shi M, Pan W, Tabel H. Experimental African trypanosomiasis: IFN-γ mediates early mortality. Eur J Immunol 2003;33:108-18.
75. Shi M, Wei G, Pan W, Tabel H. Trypanosoma congolense infections: antibody-mediated phagocytosis by Kupffer cells. J Leuko Biol 2004;76:399-405.
76. Namangala B, De Baetselier P, Brys L et al. Attenuation of Trypanosoma brucei is associated with reduced immunosuppression and concomitant production of Th2 lymphokines. J Infect Dis 2000;181:1110-20.
77. Adachi K, Tsutsui H, Kashiwamura S et al. Plasmodium berghi infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol 2001;167:5928-34.
78. Magez S, Radwanska M, Drennan M et al. Interferon-gamma and nitric oxide in collaboration with antibodies are key protective host immune factors during Trypanosoma congolense Tc13 infections. J Infect Dis 2006;193:575-83.
79. Magez S, Radwanska M, Drennan M et al. Tumor necrosis factor (TNF) receptor-1 (TNFp55) signal transduction and macrophage-derived soluble TNF are crucial for nitric oxide-mediated Trypanosoma congolense parasite killing. J Infect Dis 2007;196:954-62.
80. Namangala B, De Baetselier P, Beschin A. Both Type-I and Type-II responses contribute to murine trypanotolerance. J Vet Med Sci 2009;71:313-8.
81. Vincendeau P, Dauloude S, Veyret B, Darde ML, Bouteille B, Lemesre JL. Nitric oxide-mediated cytostatic activity on Trypanosoma brucei gambiense and Trypanosoma brucei brucei. Exp Parasitol 1992;75:353-60.
82. Hertz CJ, Mansfield JM. IFN-gamma-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis. Cell Immunol 1999;192:24-32.
83. Sternberg JM, Mabbott NA, Sutherland IA, Liew FY. Inhibition of nitric oxide synthesis leads to reduced parasitemia in murine Trypanosoma brucei infection. Infect Immun 1994;62:2135-7.
84. Daulouede S, Bouteille B, Moynet D et al. Human macrophage tumor necrosis factor (TNF)-alpha production induced by Trypanosoma brucei gambiense and the role of TNF-alpha in parasite control. J Infect Dis 2001;183:988-91.
85. Baral TN, De Baetselier P, Brombacher F, Magez S. Control of Trypanosoma evansi infection is IgM mediated and does not require a type I inflammatory response. J Infect Dis 2007;195:513-20.
86. Shi MQ, Wei GJ, Tabel H. Trypanosoma congolense infections: MHC class II-restricted immune responses mediate either protection or disease, depending on IL-10 function. Parasite Immunol 2007;29:107-11.
87. De Trez C, Magez S, Akira S et al. iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57Bl/6 resistant mice. PLoS Pathog 2009;5:e1000494.
88. Aldridge JR Jr, Mosely CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009;106:5306-11.
89. Courtin D, Argiro L, Jamonneau V et al. Interest of tumor necrosis factor-alpha -308G/A and interleukin-10-592 C/A polymorphisms in human African trypanosomiasis. Infect Genet Evol 2006;6:123-9.
90. Taylor K, Mertens B, Lutje V, Saya R. Trypanosoma congolense infection of trypanotolerant N'Dama (Bos taurus) cattle is associated with decreased secretion of nitric oxide by interferon-γ-activated monocytes and increased transcription of interleukin-10. Parasite Immunol 1998;20:421-9.
91. Mertens B, Taylor K, Muriuki C, Rocchi M. Cytokine mRNA profiles in trypanotolerant and trypanosusceptible cattle infected with the protozoan parasite Trypanosoma congolense: protective role for interleukin-4? J Interferon Cytokine Res 1999;19:59-65.
92. Hunter CA, Ellis-Neyes LA, Slifer T et al. IL-10 is required to prevent immune hypersensitivity during infection with Trypanosoma cruzi. J Immunol 1997;158:3311-6.
93. Namangala B, Brys L, Magez S, De Baetselier P, Beschin A. Trypanosoma brucei brucei infection impairs MHC Class II antigen presentation capacity of macrophages. Parasite Immunol 2000;22:361-70.
94. Namangala B. How the African trypanosomes evade host immune killing. Parasite Immunol 2011;33:430-7.
95. Hatcher FM, Kuhn RE. Destruction of T. cruzi by natural killer cells. Science 1982;218:295-6.
96. Albright JW, Jiang D, Albright JF. Innate control of the early course of infection in mice inoculated with Trypanosoma musculi. Cell Immunol 1997;176:146-52.
97. Korbel DS, Finney OC, Riley EM. Natural killer cells and innate immunity to protozoan pathogens. Int J Parasitol 2004;34:1517-28.
98. Namangala B, Sugimoto C, Inoue N. Effects of exogenous transforming factor β on Trypanosoma congolense infection in mice. Infect Immun 2007;75:1878-85.
99. Boysen P, Storset AK. Bovine natural killer cells. Vet Immunol Immunopathol 2009;130:163-77.